医学
2型神经纤维瘤病
耐受性
内科学
不利影响
血管内皮生长因子
临床终点
贝伐单抗
不良事件通用术语标准
外科
肿瘤科
胃肠病学
神经鞘瘤
化疗
血管内皮生长因子受体
临床试验
作者
Ryota Tamura,Yoshiharu Yamanobe,Masato Fujioka,Yukina Morimoto,Mariko Fukumura,Masato Nakaya,Yumiko Oishi,Mizuto Sato,Ryo Ueda,Hirokazu Fujiwara,Tetsuro Hikichi,Shinobu Noji,Naoki Oishi,Hiroyuki Ozawa,Kaoru Ogawa,Yutaka Kawakami,Takayuki Ohira,Kazunari Yoshida,Masahiro Toda
摘要
The humanized antivascular endothelial growth factor (VEGF) antibody bevacizumab (Bev) is efficacious for the treatment of NF2-related schwannomatosis (NF2), previously known as neurofibromatosis type 2. This study evaluated the safety and efficacy of a VEGF receptor (VEGFR) vaccine containing VEGFR1 and VEGFR2 peptides in patients with NF2 with progressive schwannomas (jRCTs031180184).
科研通智能强力驱动
Strongly Powered by AbleSci AI
pluto
cdercder
Oracle
bc
qiao
笨笨芯
平常的毛豆
昏睡的蟠桃
研友_Y59785
wy.he
小飞飞
iNk
归尘
我剑也未尝不利
xiahou
余味
back you up
科研小民工
高大凌寒
冰魂
皖公网安备34019202002308
